Cellerant Therapeutics of San Carlos, Ca. has added $9 million to its second round, bringing the total to $25 million. Participants in this second closing include Camelot Ventures, George Rathmann and Eminent Venture Capital Corp.
"Since the first close of our Series B, Cellerant has made significant progress in advancing our purified hematopoietic stem cell infusion, CLT-001, toward the clinic for sickle cell disease," said Cellerant CEO Bruce Cohen. "We expect that trial to be under way early next year. This Series B funding will allow us to advance the CLT-001 sickle cell program as well as CLT-001 for the treatment of autoimmune diseases and our cell-based product CLT-008 for the treatment of radiation- and chemotherapy-induced neutropenia."
- read this release for more